文献速递生殖医学

全胚冷冻策略与新鲜移植策略分配后近期心理社会福祉比较:一项随机对照试验的子研究

Psychosocial wellbeing shortly after allocation to a freeze-all strategy compared with a fresh transfer strategy in women and men: a sub-study of a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2023-01-01

该研究为多中心随机对照试验的子研究,纳入460名女性和396名男性伴侣,随机分配至全胚冷冻策略或新鲜移植策略,在揭盲后6天(取卵后4天)填写问卷。结果显示男女两组心理社会福祉总体相似,但全胚冷冻组女性抑郁症状和情绪波动略高,校正多重检验后抑郁症状差异不再显著。

要点

  • 全胚冷冻组与新鲜移植组男性在情绪反应、生活质量、不育相关压力和婚姻获益方面无差异。
  • 全胚冷冻组女性抑郁症状(P=0.045)和情绪波动(P=0.001)略高于新鲜移植组。
  • 校正多重检验后,两组女性抑郁症状差异不再显著。

核心结论

  • 全胚冷冻策略与新鲜移植策略相比,男女心理社会福祉总体相似,但全胚冷冻组女性抑郁症状和情绪波动略高。
  • 校正多重检验后,女性抑郁症状差异不再显著。

研究设计与样本

  • 多中心随机对照试验的子研究,纳入460名女性和396名男性伴侣,来自丹麦和瑞典8家公共生育诊所及西班牙1家私人诊所,2016年5月至2018年9月。
  • 参与者按1:1随机分配至全胚冷冻策略(推迟胚胎移植至后续改良自然月经周期)或新鲜移植策略(激素刺激周期移植),揭盲后6天(取卵后4天)填写自报问卷。

主要发现

  • 问卷应答率女性90.7%,男性90.2%;全胚冷冻组207名女性和179名男性完成问卷,新鲜移植组204名女性和178名男性完成问卷。
  • 男性两组在任何探索的心理社会福祉方面均无差异。
  • 全胚冷冻组女性抑郁症状(P=0.045)和情绪波动(P=0.001)略高于新鲜移植组。
  • 校正多重检验后,两组女性抑郁症状差异不再显著;其他心理社会福祉方面无额外差异。
  • 两组男女自报治疗期间生活质量相似,但略低于非生育治疗时的生活质量。

临床怎么用

  • 作者认为,尽管全胚冷冻组抑郁症状和情绪波动略高,但不应因担心延迟胚胎移植带来的情绪压力而影响临床推荐的全胚冷冻策略的采用。
  • 作者强调,只要在开始治疗前向患者提供全面的治疗策略信息,两组其他心理社会福祉方面具有可比性。

局限性

  • 尽管应答率高,但不能排除选择偏倚。
  • 问卷为取卵后4天的一次性评估,不能反映整个治疗过程,需在完整治疗周期后评估才能对全胚冷冻的心理社会后果得出确切结论。
  • 研究为随机对照试验,假设心理社会特征在两组间均匀分布,因此认为两组间已识别的心理社会差异不太可能在基线时已存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is the psychosocial wellbeing affected in women and men shortly after allocation to a freeze-all strategy with postponement of embryo transfer compared to a fresh transfer strategy? SUMMARY ANSWER: In general, psychosocial wellbeing (i.e. emotional reactions to the treatment, quality-of-life, infertility-related stress, and marital benefit) was similar in women and men allocated to a freeze-all versus those allocated to a fresh-transfer strategy 6 days after disclosure of treatment strategy (i.e. 4 days after oocyte retrieval), although women in the freeze-all group reported a slightly higher degree of depressive symptoms and mood swings compared to women in the fresh transfer group. WHAT IS KNOWN ALREADY: The use of a freeze-all strategy, i.e. freezing of the entire embryo cohort followed by elective frozen embryo transfer in subsequent cycles has increased steadily over the past decade in assisted reproductive technology (ART). This strategy essentially eliminates the risk of ovarian hyperstimulation syndrome and has proven beneficial regarding some reproductive outcomes in subgroups of women. However, patients experience a longer time interval between oocyte retrieval and embryo transfer, hence a longer time to pregnancy, possibly adding additional stress to the ART treatment. So far, little focus has been on the possible psychosocial strains caused by postponement of embryo transfer. STUDY DESIGN, SIZE, DURATION: This is a self-reported questionnaire based sub-study of a multicentre randomized controlled trial (RCT) including 460 women and 396 male partners initiating their first, second, or third treatment cycle of invitro fertilisation or intracytoplasmic sperm injection (ICSI) from May 2016 to September 2018. This sub-study was included in the primary project protocol and project plan for the RCT, as psychosocial wellbeing was considered a secondary outcome. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women from eight public fertility clinics in Denmark and Sweden and one private clinic in Spain were randomized in a 1:1 ratio on the day of inclusion (menstrual cycle day 2 or 3) to either a freeze-all strategy with postponement of embryo transfer to a subsequent modified natural menstrual cycle or a fresh transfer strategy with embryo transfer in the hormone stimulated cycle. Treatment allocation was blinded until the day of the ovulation trigger. Women and their male partners were asked to complete a validated self-reported questionnaire 6 days after unblinding of treatment group allocation, corresponding to 4 days after oocyte retrieval, investigating their psychosocial wellbeing related to the treatment defined as emotional reactions to the treatment, quality-of-life, infertility-related stress, and marital benefit. The questionnaire included items from the Copenhagen Multi-Centre Psychosocial Infertility (COMPI) Fertility Problem Stress Scales and the COMPI Marital Benefit Measure. MAIN RESULTS AND THE ROLE OF CHANCE: Baseline characteristics were comparable between the two groups for both women and men. In total, response rates were 90.7% for women and 90.2% for men. In the freeze-all group, 207 women and 179 men completed the questionnaire compared with 204 women and 178 men in the fresh transfer group. Men in the two treatment groups did not differ in any of the explored aspects of psychosocial wellbeing (i.e. emotional reactions to the treatment, quality-of-life, infertility-related stress, and marital benefit) 6 days after disclosure of treatment strategy. Women in the freeze-all group reported a slightly higher degree of depressive symptoms (P = 0.045) and mood swings (P = 0.001) (i.e. variables included in 'emotional reactions to treatment') compared to women in the fresh transfer group. When adjusted for multiple testing, depressive symptoms were no longer significantly different between the two groups. No additional differences in psychosocial wellbeing were found. Self-reported quality-of-life during treatment was also rated as similar between the two groups in both women and men, but was slightly lower than they would rate their quality-of-life when not in fertility treatment. LIMITATIONS, REASONS FOR CAUTION: Although response rates were high, selection bias cannot be excluded. As this study was an RCT, we assume that psychosocial characteristics of the participants were equally distributed in the two groups, thus it is unlikely that the identified psychosocial differences between the freeze-all and fresh transfer group were present already at baseline. Furthermore, the questionnaire was completed as a one-time assessment 4 days after oocyte retrieval, thus not reflecting the whole treatment process, whereas an assessment after the full completed treatment cycle is needed to draw firm conclusions about the psychosocial consequences of the whole waiting period. However, a question posted that late would be highly biased on whether or not a pregnancy had been achieved. WIDER IMPLICATIONS OF THE FINDINGS: The results indicate that individuals in the freeze-all group exhibited slightly higher levels of depressive symptoms and mood swings compared to those in the fresh transfer group. Nevertheless, it is important to note that any worries related to potential emotional strains stemming from delaying embryo transfer should not overshadow the adoption of a freeze-all approach in cases where it is clinically recommended. As long as patients are provided with comprehensive information about the treatment strategy before initiating the process, it is worth emphasising that other aspects of psychosocial wellbeing were comparable between the two groups. STUDY FUNDING/COMPETING INTEREST(S): The study is part of the Reprounion collaborative study, co-financed by the European Union, Interreg V Öresund-Kattegat-Skagerrak. L.P. reports financial support from Merck A/S. H.S.N. reports grants from Freya Biosciences ApS, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordic Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Ole Kirks Fond and Independent Research Fund Denmark and personal fees from Ferring Pharmaceuticals, Merck A/S, Astra Zeneca, Cook Medical, IBSA Nordic and Gedeon Richter. H.S.N is founder and chairman of the Maternity Foundation and co-developed the Safe Delivery App (non-profit). N.C.F. reports grants from Gedeon Richter, Merck A/S, Cryos International and financial support from Ferring Pharmaceuticals, Merck A/S and Gedeon Richter. N.C.F. is chairman in the steering committee for the guideline groups for The Danish Fertility Society (non-profit). P.H. reports honoraria from Merch A/S, IBSA Nordic and Gedeon Richter. A.L.M.E. reports grants and financial support from Merck A/S and Gedeon Richter. A.P. reports grants from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S and personal fees from Preglem S.A., Novo Nordic Foundation, Ferring Pharmaceuticals, Gedeon Richter, Cryos International, Merch A/S, Theramex and Organon and the lend of embryoscope to the institution from Gedeon Richter. All other authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov NCT02746562.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Pilegaard SP, Schmidt L, Stormlund S, et al. Psychosocial wellbeing shortly after allocation to a freeze-all strategy compared with a fresh transfer strategy in women and men: a sub-study of a randomized controlled trial. Hum Reprod. 2023. PMID: 37742131. doi:10.1093/humrep/dead188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。